{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-153667","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.868168+00:00","generated_at":"2026-06-01T06:34:47.932498+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium reports Phase 2 topline data for EQ101 in alopecia areata; 20% of completers achieved SALT ≤20","bullets":["Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.","In moderate-to-severe subgroup (n=17), 29% achieved SALT ≤20; mean improvement 18.4% from baseline.","EQ101 well tolerated, no SAEs; 98.9% AEs Grade 1/2; common: URI, headache, fatigue; two Grade 3 events.","Preliminary PD data show reduction of CD132 on CD8 and NK cells, consistent with target engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-153667","json":"https://secwatch.observer/filing/0001193125-24-153667.json","markdown":"https://secwatch.observer/filing/0001193125-24-153667.md","text":"https://secwatch.observer/filing/0001193125-24-153667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/0001193125-24-153667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/d842173d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:34:47.932498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}